Innovation Pharmaceuticals Stock Probability of Future Pink Sheet Price Finishing Under 0.0043

IPIX Stock  USD 0.0003  0.0001  25.00%   
Innovation Pharmaceuticals' future price is the expected price of Innovation Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Innovation Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Innovation Pharmaceuticals Backtesting, Innovation Pharmaceuticals Valuation, Innovation Pharmaceuticals Correlation, Innovation Pharmaceuticals Hype Analysis, Innovation Pharmaceuticals Volatility, Innovation Pharmaceuticals History as well as Innovation Pharmaceuticals Performance.
  
Please specify Innovation Pharmaceuticals' target price for which you would like Innovation Pharmaceuticals odds to be computed.

Innovation Pharmaceuticals Target Price Odds to finish below 0.0043

The tendency of Innovation Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay under $ 0  after 90 days
 0.0003 90 days 0 
close to 99
Based on a normal probability distribution, the odds of Innovation Pharmaceuticals to stay under $ 0  after 90 days from now is close to 99 (This Innovation Pharmaceuticals probability density function shows the probability of Innovation Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Innovation Pharmaceuticals price to stay between its current price of $ 0.0003  and $ 0  at the end of the 90-day period is about 61.36 .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 1.98 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Innovation Pharmaceuticals will likely underperform. In addition to that Innovation Pharmaceuticals has an alpha of 14.6298, implying that it can generate a 14.63 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Innovation Pharmaceuticals Price Density   
       Price  

Predictive Modules for Innovation Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Innovation Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.000.000350.02
Details
Intrinsic
Valuation
LowRealHigh
0.000.000250.02
Details

Innovation Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Innovation Pharmaceuticals is not an exception. The market had few large corrections towards the Innovation Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Innovation Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Innovation Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
14.63
β
Beta against Dow Jones1.98
σ
Overall volatility
0.0005
Ir
Information ratio 0.27

Innovation Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Innovation Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Innovation Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Innovation Pharmaceuticals is way too risky over 90 days horizon
Innovation Pharmaceuticals has some characteristics of a very speculative penny stock
Innovation Pharmaceuticals appears to be risky and price may revert if volatility continues
Innovation Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Innovation Pharmaceuticals currently holds 1.24 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Innovation Pharmaceuticals has a current ratio of 0.59, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation to invest in growth at high rates of return. When we think about Innovation Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 18 K. Net Loss for the year was (7.04 M) with profit before overhead, payroll, taxes, and interest of 18 K.
Innovation Pharmaceuticals currently holds about 2.97 M in cash with (6.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Innovation Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Innovation Pink Sheet often depends not only on the future outlook of the current and potential Innovation Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Innovation Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding472.2 M
Short Long Term Debt250 K
Shares Float439.3 M

Innovation Pharmaceuticals Technical Analysis

Innovation Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Innovation Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Innovation Pharmaceuticals. In general, you should focus on analyzing Innovation Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

Innovation Pharmaceuticals Predictive Forecast Models

Innovation Pharmaceuticals' time-series forecasting models is one of many Innovation Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Innovation Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about Innovation Pharmaceuticals

Checking the ongoing alerts about Innovation Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Innovation Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Innovation Pharmaceuticals is way too risky over 90 days horizon
Innovation Pharmaceuticals has some characteristics of a very speculative penny stock
Innovation Pharmaceuticals appears to be risky and price may revert if volatility continues
Innovation Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Innovation Pharmaceuticals currently holds 1.24 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Innovation Pharmaceuticals has a current ratio of 0.59, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation to invest in growth at high rates of return. When we think about Innovation Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 18 K. Net Loss for the year was (7.04 M) with profit before overhead, payroll, taxes, and interest of 18 K.
Innovation Pharmaceuticals currently holds about 2.97 M in cash with (6.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Additional Tools for Innovation Pink Sheet Analysis

When running Innovation Pharmaceuticals' price analysis, check to measure Innovation Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation Pharmaceuticals is operating at the current time. Most of Innovation Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Innovation Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation Pharmaceuticals' price. Additionally, you may evaluate how the addition of Innovation Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.